N-Acetyltransferase-2 (NAT2) genotype frequency among Jordanian volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 10, 2010, Pages 688-694

  Jarrar, Y B ^a   Ismail, S ^a   Irshaid, Y M ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Frequency; Genotypes; Jordanians; N acetyltransferase 2

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; GENOMIC DNA;

ACETYLATION; ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE FREQUENCY; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; JORDAN; MALE; MIDDLE EAST; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VOLUNTEER;

EID: 77957679804     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48688     Document Type: Article

References (36)

1. Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol. 2007; 21: 155-158. (Pubitemid 47061612)
2. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab. 2008; 9: 487-497.
3. Kshirsagar NA, Pohujani SM, Takle MR, Acharya VN, Satoskar RS. Sulphadimidine acetylation status in Gujarati and Marathi population. J Postgrad Med. 1987; 33: 128-133.
4. Gil JP, Lechner MC. Increased frequency of wildtype arylamine-N- acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis. 1998; 19: 37-41.
5. Lubin JH, Kogevinas M, Silverman D, Malats N, Garcia-Closas M, Tardón A, Hein DW, Garcia- Closas R, Serra C, Dosemeci M, Carrato A, Rothman N. Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in Spanish bladder cancer study. Int J Epidemiol. 2007; 36: 236-241.
6. Malik MA, Upadhyay R, Modi DR, Zargar SA, Mittal B. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley. Arch Med Res. 2009; 40: 416-423.
7. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Association of genetic polymorphisms of N-acetyltransferase 2 and susceptibility to esophageal cancer in North Indian Population. Cancer Invest. 2007; 25: 340-346. (Pubitemid 47185079)
8. Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, Sherman ME, Szeszenia-Dabrowska N, Chanock S, Garcia-Closas M. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer. 2006; 119: 1961-1969. (Pubitemid 44356858)
9. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Michalek AM, Laughlin R, Nemoto T, Gillenwater KA, Harrington AM, Shields PG. Cigarette smoking, Nacetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA.1996; 276: 1494-1501.
10. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Dabrowska-Zamojcin E, Gawronska-Szklarz B. The influence of N-acetyltransferase 2 polymorphism on rheumatoid arthritis activity. Clin Exp Rheumatol. 2004; 22: 99-102. (Pubitemid 38232815)
11. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Brit J Rheumatol. 1997; 36: 1089-1094. (Pubitemid 27488689)
12. Irshaid Y, Al-Hadidi H, Abuirjeie M, Latif A, Sartawi O, Rawashdeh N. Acetylator phenotypes of Jordanian diabetics. Eur J Clin Pharmacol. 1992; 43: 621-623.
13. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab. 2008; 9: 738-784.
14. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9: 29-42. (Pubitemid 30062907)
15. Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR, Velayati AA. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol. 2004; 60: 467-471. (Pubitemid 39350159)
16. Irshaid Y, Al-Hadidi H, Abuirjeie M, Rawashdeh N. N-acetylation phenotyping using dapsone in a Jordanian population. Brit J Clin Pharmacol. 1991; 32: 289-293.
17. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Plácido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis. 1999; 20: 1225-1229.
18. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics. 1994; 4: 125-134. (Pubitemid 24210930)
19. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995; 57: 581-592.
20. Bu R, Gutiérrez MI, Al-Rasheed M, Belgaumi A, Bhatia K. Variable drug metabolism genes in Arab population. Pharmacogenomics J. 2004; 4: 260-266. (Pubitemid 39136769)
21. Mittal RD, Srivastava DS, Mandhani A. NAT2 gene polymorphism in bladder cancer: a study from North India. International Braz J Urol. 2004; 30: 279-288. (Pubitemid 39255892)
22. Deloménie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics. 1996; 6: 177-185. (Pubitemid 26153360)
23. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, Ahmed MS, Mizugaki M. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Brit J Clin Pharmacol. 2003; 55: 560-569. (Pubitemid 36783197)
24. Torkaman-Boutorabi A, Hoormand M, Naghdi N, Bakhshayesh M, Milanian I. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Clin Exp Pharmacol Physiol. 2007; 34: 1207-1211.
25. Magalon H, Patin E, Austerlitz F, Hegay T, Aldashev A, Quintana-Murci L, Heyer E. Population genetic diversity of NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur J Hum Genet. 2008; 16: 243-251.
26. Yalin S, Hatungil R, Tamer L, Ates N A, Dogruer N, Yildrim H, Karakas S, Atik U. N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. Cell Biochem Funct. 2007; 25: 407-411. (Pubitemid 47066716)
27. Ajlouni K, Khader Y S, Batieha A, Ajlouni H, El- Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complications. 2008; 22: 317-324.
28. Luca F, Bubba G, Basile M, Brdicka R, Michalodimitrakis E, Rickards O, Vershubsky G, Quintana- Murci L, Kozlov AI, Novelletto A. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS ONE. 2008; 3: 3136.
29. Ayanacioglu AS, Cascorbi I, Mrozikiewicz P M, Roots I. Arylamine N-acetyltransferase (NAT2) genotype in a Turkish population. Pharmacogenetics. 1997; 7: 327-331.
30. Kuhn UD, Anschütz M, Schmücker K, Schug BS, Hippius M, Blume HH. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. Int J Clin Pharmacol Ther. 2010; 48: 1-10.
31. Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002; 9: 163-165.
32. Yamada S, Tang M, Richardson K, Halaschek- Wiener J, Chan M, Cook VJ, Fitzgerald JM, Elwood RK, Brooks-Wilson A, Marra F. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics. 2009; 10: 1433-1445.
33. Kameda H, Mimori T, Kaburaki J, Fujii T, Takahashi T, Akaishi M, Ikeda, Y. Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. Br J Rheumatol. 1998; 37: 1236-1239. (Pubitemid 128453055)
34. Tsujimoto G, Horai Y, Ishizaki T, Itoh K. Hydralazine- induced peripheral neuropathy seen in a Japanese slow acetylator patient. Br J Clin Pharmacol. 1981; 11: 622-625. (Pubitemid 11112446)
35. Kang TS, Jin SK, Lee JE, Woo SW, Roh J. Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. J Clin Pharm Ther. 2009; 34: 709-718.
36. Teixeira RL, Silva FP Jr, Silveira AR, Cabello PH, Mendonça-Lima L, Rabahi MF, Kritski AL, Mello FC, Suffys PN, de Miranda AB, Santos AR. Sequence analysis of NAT2 gene in Brazilians: identification of undescribed single nucleotide polymorphisms and molecular modeling of the N-acetyltransferase 2 protein structure. Mutat Res. 2010; 5: 43-49.